克罗恩病患者甲氨蝶呤的治疗药物监测
这项多中心前瞻性队列研究纳入80例开始皮下甲氨蝶呤且未使用生物制剂的克罗恩病患者,随访12个月,分析红细胞甲氨蝶呤多聚谷氨酸(MTX-PG)浓度与药物生存、疗效及毒性的关系。结果显示较高的MTX-PG3浓度与更高的甲氨蝶呤药物生存率、更低的粪便钙卫蛋白水平及生化应答相关,与胃肠道不耐受较少相关。
要点
- 较高的MTX-PG3浓度与更高的甲氨蝶呤药物生存率相关(HR 0.86,95%CI 0.75-0.99)。
- 较高的MTX-PG3浓度与更低的粪便钙卫蛋白水平相关(β -3.7,SE 1.3,p<0.01)。
- MTX-PG3与Harvey Bradshaw指数或肝毒性无稳健关联。
核心结论
- 较高的MTX-PG3浓度与更好的甲氨蝶呤药物生存率和更低的粪便钙卫蛋白水平相关。
- 因此,若能建立目标浓度,MTX-PG3可用于治疗药物监测。
研究设计与样本
- 多中心前瞻性队列研究,纳入80例开始皮下甲氨蝶呤且未使用生物制剂的克罗恩病患者,随访12个月。
主要发现
- 12个月访视后,21例患者(26%)仍在使用皮下甲氨蝶呤单药治疗。
- 21例因疾病活动停止,29例因毒性停止,4例因两者停止,5例因其他原因结束研究参与或停止甲氨蝶呤。
- 较高的MTX-PG3浓度与更高的甲氨蝶呤药物生存率相关(HR 0.86,95%CI 0.75-0.99)。
- 较高的MTX-PG3浓度与更低的粪便钙卫蛋白水平相关(β -3.7,SE 1.3,p<0.01)。
- 较高的MTX-PG3浓度与生化应答相关(基线粪便钙卫蛋白>250 μg/g者降至≤250 μg/g;OR 1.1,95%CI 1.0-1.3)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate-polyglutamate (MTX-PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease (CD). AIM: To investigate the relationship between MTX-PGs and methotrexate drug survival, efficacy and toxicity METHODS: In a multicentre prospective cohort study, patients with CD starting subcutaneous methotrexate without biologics were included and followed for 12 months. Primary outcome was subcutaneous methotrexate discontinuation or requirement for step-up therapy. Secondary outcomes included faecal calprotectin (FCP), Harvey Bradshaw Index (HBI), hepatotoxicity and gastrointestinal intolerance. Erythrocyte MTX-PGs were analysed at weeks 8, 12, 24 and 52 or upon treatment discontinuation. RESULTS: We included 80 patients with CD (mean age 55 ± 13y, 35% male) with a median FCP of 268 μg/g (IQR 73-480). After the 12-month visit, 21 patients (26%) were still on subcutaneous methotrexate monotherapy. Twenty-one patients stopped because of disease activity, 29 because of toxicity, and four for both reasons. Five patients ended study participation or stopped methotrexate for another reason. A higher MTX-PG3 concentration was associated with a higher rate of methotrexate drug survival (HR 0.86, 95% CI 0.75-0.99), lower FCP (β -3.7, SE 1.3, p < 0.01) and with biochemical response (FCP ≤250 if baseline >250 μg/g; OR 1.1, 95% CI 1.0-1.3). Higher MTX-PGs were associated with less gastrointestinal intolerance. There was no robust association between MTX-PGs and HBI or hepatotoxicity. CONCLUSIONS: Higher MTX-PG3 concentrations are related to better methotrexate drug survival and decreased FCP levels. Therefore, MTX-PG3 could be used for TDM if a target concentration can be established.
引用
- van de Meeberg MM, Fidder HH, Oldenburg B, et al. Therapeutic drug monitoring of methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2023. PMID: 37767910. doi:10.1111/apt.17719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。